Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05506800 Suspended - Breast Cancer Clinical Trials

Guangzhou Women's Health Cohort Study (GWHCS)

Start date: March 3, 2016
Study type: Observational

The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

NCT ID: NCT05343013 Suspended - Colorectal Cancer Clinical Trials

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Start date: June 6, 2022
Phase: Phase 2
Study type: Interventional

To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.

NCT ID: NCT04985981 Suspended - Colorectal Cancer Clinical Trials

The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study

Start date: April 1, 2021
Study type: Observational [Patient Registry]

The Prediction of Anastomotic Insufficiency risk after Colorectal surgery (PANIC) study aims to establish a machine-learning-based application that allows for accurate preoperative prediction of patients at risk for anastomotic insufficiency after colon and colorectal surgery.

NCT ID: NCT04714983 Suspended - Breast Cancer Clinical Trials

DNX-2440 for Resectable Colorectal Liver Metastasis

Start date: February 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.

NCT ID: NCT04595604 Suspended - Colorectal Cancer Clinical Trials

Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.

Start date: September 7, 2020
Phase: N/A
Study type: Interventional

Elective surgery is the most effective treatment option for colorectal cancer, however it has been recognized to be associated with high morbidity and mortality risks. ERAS (Enhanced Recovery After Surgery) is a preoperative multimodality treatment package, which has been well investigated and proved to be effective in reducing early postoperative morbidity, mortality, length of hospital stay and hospital costs, as well. Still, a good proportion of patients are not suitable for ERAS program, mainly based on lack of compliance and the impaired physical function before surgery. Trimodal Prehabilitation Program is a recently introduced preoperative preparation (training) program, which addresses improvement of physical, mental and nutritional status of the high risk elective surgery patients. This study aims to investigate the benefit of all efforts of a 4-6-week preoperative preparation program (Prehabilitation) being added to an established ERAS protocol. Additionally the effect of trimodal prehabilitation on gut microbiom diversity and its relation to clinical outcome will be analyzed.

NCT ID: NCT02494973 Suspended - Colorectal Cancer Clinical Trials

Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases

Start date: May 26, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Currently, no adjuvant study with hepatic arterial infusion in the adjuvant setting is opened. Recently, the results of a phase II study (NCT00268463, NSABP-C-09) assessing the potential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR, after resection of CRLM have been reported. The primary end point was 2-year survival. Fifty-five of 76 eligible patients were able to initiate protocol-directed therapy and completed median of six cycles (range, one to six). Three postoperative or treatment-related deaths were reported. Overall, 88% of evaluable patients were alive at 2 years. With a median followup of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver. Median disease-free survival was 32.7 months. In conclusion alternating HAI of FUDR and systemic capecitabine and oxaliplatin met the prespecified end point of higher than 85% survival at 2 years and were clinically tolerable.

NCT ID: NCT00609310 Suspended - Colorectal Cancer Clinical Trials

Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Prove the hypothesis that dietary supplementation with bioflavonoids will diminish the recurrence rate of colonic neoplasia, we will implement a clinical trial comparing bioflavonoids and placebo in a double blind randomized clinical trial. To use a standardised supplementation of bioflavonoids, a commercially available preparation (Flavo-Natin®) will be used.